• Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that are lower than those currently available in single pill combinations, designed to deliver the blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, with an established safety profile
• George Medicines receives upfront licensing fee and is eligible for regulatory and commercial milestone payments, as well as a future recurring revenue stream through a stepped royalty rate on sales in Brazil
• Third licensing agreement for GMRx2 follows deals with Bausch Health in Canada, Mexico, Colombia and Central America, and with Azurity Pharmaceuticals in the US
  
  

George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Biolab Farmacêutica (“Biolab”), one of Brazil’s largest pharmaceutical companies, granting Biolab exclusive rights to seek regulatory approval of, and to commercialize, GMRx2 in Brazil.

GMRx2 is an innovative single pill combination of three medicines, telmisartan, amlodipine and indapamide, for the treatment of hypertension, developed in three doses, including two doses that are lower than those currently available in single pill combinations. Its multi-mechanism approach and available doses are formulated to deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, with the safety profile of established antihypertensive medications.

Most patients with hypertension will require two or more medicines to bring their blood pressure under control, and globally recognized treatment guidelines acknowledge the preferred use of single pill combination therapy and the benefit of their early use.^1,2,3

Mark Mallon, Chief Executive Officer of George Medicines, said: “This partnership in Brazil further strengthens our global commercial strategy for GMRx2 and follows on swiftly from the product’s regulatory approval in the US and licensing agreements covering the US, Canada, Mexico, Colombia and Central America markets. The clinically-proven efficacy of this triple combination product, with its multiple dosing options including two doses that are lower than those currently available in single pill combinations, coupled with its established safety profile, has the potential to address key challenges in current hypertension treatment approaches. Through our partnership with Biolab we have an opportunity with GMRx2 to meaningfully advance cardiovascular care in Brazil.”

Fabio Amorosino, Chief Executive Officer of Biolab Farmacêutica, said: “The partnership with George Medicines for the exclusive commercialization of GMRx2 reinforces Biolab’s strategic presence in the cardiovascular segment. The medication, which will undergo regulatory approval in Brazil, represents a significant innovation in hypertension treatment. With a solid infrastructure and strong medical presence, we are well prepared to expand access to effective and safe healthcare solutions for the population.”

Under the terms of the licensing agreement, George Medicines will receive an upfront licensing fee and is eligible for regulatory and commercial milestone payments, as well as a future recurring revenue stream through a stepped royalty rate on sales of GMRx2 in the licensed territory. In return, Biolab Farmacêutica is granted a license to exclusively commercialize GMRx2, supplied by George Medicines. Biolab is responsible for seeking regulatory approval of GMRx2, with support from George Medicines.

This is George Medicines’ third licensing and supply agreement for GMRx2, following the agreement established with Bausch Health in January 2025 granting exclusive rights in Canada, Mexico, Colombia and Central America, and with Azurity Pharmaceuticals in July 2025 granting exclusive rights in the US. Further collaborations are anticipated as part of George Medicines’ commitment to bring the value of this important medicine to patients globally.

George Medicines is an independent spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes with a focus on addressing global health inequity. The Company is backed by George Health, the commercial arm of The George Institute, and Brandon Capital, Australia’s leading life sciences venture capital firm.